Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

MLAB vs NOVT vs MKSI vs TRMB

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
MLAB
Mesa Laboratories, Inc.

Hardware, Equipment & Parts

TechnologyNASDAQ • US
Market Cap$586M
5Y Perf.-59.8%
NOVT
Novanta Inc.

Hardware, Equipment & Parts

TechnologyNASDAQ • US
Market Cap$4.86B
5Y Perf.+32.7%
MKSI
MKS Inc.

Hardware, Equipment & Parts

TechnologyNASDAQ • US
Market Cap$20.25B
5Y Perf.+184.8%
TRMB
Trimble Inc.

Hardware, Equipment & Parts

TechnologyNASDAQ • US
Market Cap$14.65B
5Y Perf.+58.1%

MLAB vs NOVT vs MKSI vs TRMB — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
MLAB logoMLAB
NOVT logoNOVT
MKSI logoMKSI
TRMB logoTRMB
IndustryHardware, Equipment & PartsHardware, Equipment & PartsHardware, Equipment & PartsHardware, Equipment & Parts
Market Cap$586M$4.86B$20.25B$14.65B
Revenue (TTM)$248M$981M$4.07B$3.69B
Net Income (TTM)$4M$54M$327M$456M
Gross Margin60.6%44.4%45.2%68.8%
Operating Margin7.0%11.9%14.8%17.7%
Forward P/E11.7x38.2x30.4x20.0x
Total Debt$181M$342M$4.69B$1.39B
Cash & Equiv.$27M$381M$675M$253M

MLAB vs NOVT vs MKSI vs TRMBLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

MLAB
NOVT
MKSI
TRMB
StockMay 20May 26Return
Mesa Laboratories, … (MLAB)10040.2-59.8%
Novanta Inc. (NOVT)100132.7+32.7%
MKS Inc. (MKSI)100284.8+184.8%
Trimble Inc. (TRMB)100158.1+58.1%

Price return only. Dividends and distributions are not included.

Quick Verdict: MLAB vs NOVT vs MKSI vs TRMB

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MLAB and TRMB are tied at the top with 3 categories each — the right choice depends on your priorities. Trimble Inc. is the stronger pick specifically for profitability and margin quality and capital preservation and lower volatility. MKSI also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
MLAB
Mesa Laboratories, Inc.
The Income Pick

MLAB carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 0 yrs, beta 1.78, yield 0.6%
  • Rev growth 11.5%, EPS growth 99.2%, 3Y rev CAGR 9.3%
  • Beta 1.78, yield 0.6%, current ratio 0.63x
  • 11.5% revenue growth vs TRMB's -2.6%
Best for: income & stability and growth exposure
NOVT
Novanta Inc.
The Long-Run Compounder

NOVT is the clearest fit if your priority is long-term compounding.

  • 8.5% 10Y total return vs MKSI's 7.5%
Best for: long-term compounding
MKSI
MKS Inc.
The Momentum Pick

MKSI is the clearest fit if your priority is momentum.

  • +306.1% vs MLAB's -11.2%
Best for: momentum
TRMB
Trimble Inc.
The Defensive Pick

TRMB is the #2 pick in this set and the best alternative if sleep-well-at-night and valuation efficiency is your priority.

  • Lower volatility, beta 1.46, Low D/E 23.9%, current ratio 1.09x
  • PEG 8.15 vs NOVT's 11.61
  • 12.4% margin vs MLAB's 1.5%
  • Beta 1.46 vs MKSI's 2.64, lower leverage
Best for: sleep-well-at-night and valuation efficiency
See the full category breakdown
CategoryWinnerWhy
GrowthMLAB logoMLAB11.5% revenue growth vs TRMB's -2.6%
ValueMLAB logoMLABLower P/E (11.7x vs 30.4x)
Quality / MarginsTRMB logoTRMB12.4% margin vs MLAB's 1.5%
Stability / SafetyTRMB logoTRMBBeta 1.46 vs MKSI's 2.64, lower leverage
DividendsMLAB logoMLAB0.6% yield, vs MKSI's 0.3%, (2 stocks pay no dividend)
Momentum (1Y)MKSI logoMKSI+306.1% vs MLAB's -11.2%
Efficiency (ROA)TRMB logoTRMB5.0% ROA vs MLAB's 0.9%, ROIC 6.8% vs 3.7%

MLAB vs NOVT vs MKSI vs TRMB — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

MLABMesa Laboratories, Inc.
FY 2025
Product
82.3%$198M
Service
17.7%$43M
NOVTNovanta Inc.
FY 2025
Robotics and Automation
32.5%$319M
Advanced Surgery
24.7%$242M
Precision Medicine
24.2%$237M
Precision Manufacturing
18.6%$182M
MKSIMKS Inc.
FY 2025
Product
87.4%$3.4B
Service
12.6%$495M
TRMBTrimble Inc.
FY 2025
Service
68.4%$2.5B
Product
31.6%$1.1B

MLAB vs NOVT vs MKSI vs TRMB — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLMLABLAGGINGNOVT

Income & Cash Flow (Last 12 Months)

TRMB leads this category, winning 3 of 6 comparable metrics.

MKSI is the larger business by revenue, generating $4.1B annually — 16.4x MLAB's $248M. TRMB is the more profitable business, keeping 12.4% of every revenue dollar as net income compared to MLAB's 1.5%. On growth, MKSI holds the edge at +15.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricMLAB logoMLABMesa Laboratories…NOVT logoNOVTNovanta Inc.MKSI logoMKSIMKS Inc.TRMB logoTRMBTrimble Inc.
RevenueTrailing 12 months$248M$981M$4.1B$3.7B
EBITDAEarnings before interest/tax$37M$179M$945M$785M
Net IncomeAfter-tax profit$4M$54M$327M$456M
Free Cash FlowCash after capex$38M$48M$401M$253M
Gross MarginGross profit ÷ Revenue+60.6%+44.4%+45.2%+68.8%
Operating MarginEBIT ÷ Revenue+7.0%+11.9%+14.8%+17.7%
Net MarginNet income ÷ Revenue+1.5%+5.5%+8.0%+12.4%
FCF MarginFCF ÷ Revenue+15.2%+4.9%+9.8%+6.9%
Rev. Growth (YoY)Latest quarter vs prior year+3.6%+8.5%+15.2%+11.8%
EPS Growth (YoY)Latest quarter vs prior year+3.1%-2.2%+53.2%+55.6%
TRMB leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

MLAB leads this category, winning 5 of 7 comparable metrics.

At 35.3x trailing earnings, TRMB trades at a 62% valuation discount to NOVT's 92.7x P/E. Adjusting for growth (PEG ratio), TRMB offers better value at 14.39x vs NOVT's 28.13x — a lower PEG means you pay less per unit of expected earnings growth.

MetricMLAB logoMLABMesa Laboratories…NOVT logoNOVTNovanta Inc.MKSI logoMKSIMKS Inc.TRMB logoTRMBTrimble Inc.
Market CapShares × price$586M$4.9B$20.2B$14.7B
Enterprise ValueMkt cap + debt − cash$740M$4.8B$24.3B$15.8B
Trailing P/EPrice ÷ TTM EPS-294.78x92.71x68.83x35.34x
Forward P/EPrice ÷ next-FY EPS est.11.71x38.25x30.36x20.01x
PEG RatioP/E ÷ EPS growth rate28.13x14.39x
EV / EBITDAEnterprise value multiple18.12x27.00x26.70x20.05x
Price / SalesMarket cap ÷ Revenue2.43x4.96x5.15x4.08x
Price / BookPrice ÷ Book value/share3.60x3.81x7.49x2.54x
Price / FCFMarket cap ÷ FCF13.86x100.38x40.74x110.00x
MLAB leads this category, winning 5 of 7 comparable metrics.

Profitability & Efficiency

Evenly matched — NOVT and TRMB each lead in 3 of 9 comparable metrics.

MKSI delivers a 12.2% return on equity — every $100 of shareholder capital generates $12 in annual profit, vs $2 for MLAB. TRMB carries lower financial leverage with a 0.24x debt-to-equity ratio, signaling a more conservative balance sheet compared to MKSI's 1.73x. On the Piotroski fundamental quality scale (0–9), MLAB scores 6/9 vs TRMB's 5/9, reflecting solid financial health.

MetricMLAB logoMLABMesa Laboratories…NOVT logoNOVTNovanta Inc.MKSI logoMKSIMKS Inc.TRMB logoTRMBTrimble Inc.
ROE (TTM)Return on equity+2.0%+4.1%+12.2%+8.0%
ROA (TTM)Return on assets+0.9%+3.0%+3.7%+5.0%
ROICReturn on invested capital+3.7%+7.4%+6.5%+6.8%
ROCEReturn on capital employed+4.9%+8.3%+7.2%+7.8%
Piotroski ScoreFundamental quality 0–96565
Debt / EquityFinancial leverage1.14x0.26x1.73x0.24x
Net DebtTotal debt minus cash$154M-$39M$4.0B$1.1B
Cash & Equiv.Liquid assets$27M$381M$675M$253M
Total DebtShort + long-term debt$181M$342M$4.7B$1.4B
Interest CoverageEBIT ÷ Interest expense2.36x4.89x2.84x12.26x
Evenly matched — NOVT and TRMB each lead in 3 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

MKSI leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in MKSI five years ago would be worth $16,648 today (with dividends reinvested), compared to $4,350 for MLAB. Over the past 12 months, MKSI leads with a +306.1% total return vs MLAB's -11.2%. The 3-year compound annual growth rate (CAGR) favors MKSI at 54.1% vs MLAB's -12.5% — a key indicator of consistent wealth creation.

MetricMLAB logoMLABMesa Laboratories…NOVT logoNOVTNovanta Inc.MKSI logoMKSIMKS Inc.TRMB logoTRMBTrimble Inc.
YTD ReturnYear-to-date+33.8%+22.6%+78.8%-21.0%
1-Year ReturnPast 12 months-11.2%+14.6%+306.1%-6.7%
3-Year ReturnCumulative with dividends-33.0%-15.2%+266.0%+30.1%
5-Year ReturnCumulative with dividends-56.5%+5.7%+66.5%-22.0%
10-Year ReturnCumulative with dividends+4.5%+853.7%+750.6%+166.8%
CAGR (3Y)Annualised 3-year return-12.5%-5.3%+54.1%+9.2%
MKSI leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

Evenly matched — MKSI and TRMB each lead in 1 of 2 comparable metrics.

TRMB is the less volatile stock with a 1.46 beta — it tends to amplify market swings less than MKSI's 2.64 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MKSI currently trades 92.0% from its 52-week high vs TRMB's 70.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricMLAB logoMLABMesa Laboratories…NOVT logoNOVTNovanta Inc.MKSI logoMKSIMKS Inc.TRMB logoTRMBTrimble Inc.
Beta (5Y)Sensitivity to S&P 5001.78x2.02x2.64x1.46x
52-Week HighHighest price in past year$131.20$149.95$326.83$87.50
52-Week LowLowest price in past year$55.45$98.27$71.49$61.63
% of 52W HighCurrent price vs 52-week peak+80.9%+90.9%+92.0%+70.7%
RSI (14)Momentum oscillator 0–10066.162.665.336.8
Avg Volume (50D)Average daily shares traded123K375K1.2M1.7M
Evenly matched — MKSI and TRMB each lead in 1 of 2 comparable metrics.

Analyst Outlook

MLAB leads this category, winning 1 of 1 comparable metric.

Analyst consensus: MLAB as "Hold", NOVT as "Buy", MKSI as "Buy", TRMB as "Buy". Consensus price targets imply 53.6% upside for TRMB (target: $95) vs -11.4% for MLAB (target: $94). For income investors, MLAB offers the higher dividend yield at 0.60% vs MKSI's 0.29%.

MetricMLAB logoMLABMesa Laboratories…NOVT logoNOVTNovanta Inc.MKSI logoMKSIMKS Inc.TRMB logoTRMBTrimble Inc.
Analyst RatingConsensus buy/hold/sellHoldBuyBuyBuy
Price TargetConsensus 12-month target$94.00$150.00$272.86$95.00
# AnalystsCovering analysts832928
Dividend YieldAnnual dividend ÷ price+0.6%+0.3%
Dividend StreakConsecutive years of raises00
Dividend / ShareAnnual DPS$0.64$0.87
Buyback YieldShare repurchases ÷ mkt cap0.0%+0.8%+0.2%+5.9%
MLAB leads this category, winning 1 of 1 comparable metric.
Key Takeaway

MLAB leads in 2 of 6 categories (Valuation Metrics, Analyst Outlook). TRMB leads in 1 (Income & Cash Flow). 2 tied.

Best OverallMesa Laboratories, Inc. (MLAB)Leads 2 of 6 categories
Loading custom metrics...

MLAB vs NOVT vs MKSI vs TRMB: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is MLAB or NOVT or MKSI or TRMB a better buy right now?

For growth investors, Mesa Laboratories, Inc.

(MLAB) is the stronger pick with 11. 5% revenue growth year-over-year, versus -2. 6% for Trimble Inc. (TRMB). Trimble Inc. (TRMB) offers the better valuation at 35. 3x trailing P/E (20. 0x forward), making it the more compelling value choice. Analysts rate Novanta Inc. (NOVT) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — MLAB or NOVT or MKSI or TRMB?

On trailing P/E, Trimble Inc.

(TRMB) is the cheapest at 35. 3x versus Novanta Inc. at 92. 7x. On forward P/E, Mesa Laboratories, Inc. is actually cheaper at 11. 7x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Trimble Inc. wins at 8. 15x versus Novanta Inc. 's 11. 61x.

03

Which is the better long-term investment — MLAB or NOVT or MKSI or TRMB?

Over the past 5 years, MKS Inc.

(MKSI) delivered a total return of +66. 5%, compared to -56. 5% for Mesa Laboratories, Inc. (MLAB). Over 10 years, the gap is even starker: NOVT returned +853. 7% versus MLAB's +4. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — MLAB or NOVT or MKSI or TRMB?

By beta (market sensitivity over 5 years), Trimble Inc.

(TRMB) is the lower-risk stock at 1. 46β versus MKS Inc. 's 2. 64β — meaning MKSI is approximately 80% more volatile than TRMB relative to the S&P 500. On balance sheet safety, Trimble Inc. (TRMB) carries a lower debt/equity ratio of 24% versus 173% for MKS Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — MLAB or NOVT or MKSI or TRMB?

By revenue growth (latest reported year), Mesa Laboratories, Inc.

(MLAB) is pulling ahead at 11. 5% versus -2. 6% for Trimble Inc. (TRMB). On earnings-per-share growth, the picture is similar: Mesa Laboratories, Inc. grew EPS 99. 2% year-over-year, compared to -71. 3% for Trimble Inc.. Over a 3-year CAGR, MLAB leads at 9. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — MLAB or NOVT or MKSI or TRMB?

Trimble Inc.

(TRMB) is the more profitable company, earning 11. 8% net margin versus -0. 8% for Mesa Laboratories, Inc. — meaning it keeps 11. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TRMB leads at 16. 9% versus 6. 8% for MLAB. At the gross margin level — before operating expenses — TRMB leads at 68. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is MLAB or NOVT or MKSI or TRMB more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Trimble Inc. (TRMB) is the more undervalued stock at a PEG of 8. 15x versus Novanta Inc. 's 11. 61x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Mesa Laboratories, Inc. (MLAB) trades at 11. 7x forward P/E versus 38. 2x for Novanta Inc. — 26. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TRMB: 53. 6% to $95. 00.

08

Which pays a better dividend — MLAB or NOVT or MKSI or TRMB?

In this comparison, MLAB (0.

6% yield), MKSI (0. 3% yield) pay a dividend. NOVT, TRMB do not pay a meaningful dividend and should not be held primarily for income.

09

Is MLAB or NOVT or MKSI or TRMB better for a retirement portfolio?

For long-horizon retirement investors, Mesa Laboratories, Inc.

(MLAB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (0. 6% yield). MKS Inc. (MKSI) carries a higher beta of 2. 64 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MLAB: +4. 5%, MKSI: +750. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between MLAB and NOVT and MKSI and TRMB?

Both stocks operate in the Technology sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

MLAB pays a dividend while NOVT, MKSI, TRMB do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

MLAB

Stable Dividend Mega-Cap

  • Sector: Technology
  • Market Cap > $100B
  • Gross Margin > 36%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

NOVT

Quality Business

  • Sector: Technology
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 5%
Run This Screen
Stocks Like

MKSI

High-Growth Disruptor

  • Sector: Technology
  • Market Cap > $100B
  • Revenue Growth > 7%
  • Net Margin > 5%
Run This Screen
Stocks Like

TRMB

Steady Growth Compounder

  • Sector: Technology
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 7%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform MLAB and NOVT and MKSI and TRMB on the metrics below

Revenue Growth>
%
(MLAB: 3.6% · NOVT: 8.5%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.